Moleculin Biotech Inc
NASDAQ:MBRX

Watchlist Manager
Moleculin Biotech Inc Logo
Moleculin Biotech Inc
NASDAQ:MBRX
Watchlist
Price: 3.62 USD 9.37% Market Closed
Market Cap: 7.5m USD

MBRX's latest stock split occurred on Dec 1, 2025

The company executed a 1-for-25 stock split, meaning that for every 25 shares held, investors received 1 new share.

Before the split, MBRX traded at 0.2727 per share. Afterward, the share price was about 6.63.

The adjusted shares began trading on Dec 1, 2025. This was MBRX's 3rd stock split, following the previous one in Mar 22, 2024.

Last Splits:
Dec 1, 2025
1-for-25
Mar 22, 2024
1-for-15
Feb 1, 2021
1-for-6
Pre-Split Price
6.8175 0.2727
Post-Split Price
6.63
Before
After
Last Splits:
Dec 1, 2025
1-for-25
Mar 22, 2024
1-for-15
Feb 1, 2021
1-for-6

Moleculin Biotech Inc
Stock Splits History

MBRX Stock Splits Timeline
Dec 1, 2025
Dec 1, 2025
Split 1-for-25
/0.04
Pre-Split Price
6.8175 0.2727
Post-Split Price
6.63
Before
After
Mar 22, 2024
Mar 22, 2024
Split 1-for-15
/0.066666666666667
Pre-Split Price
165.75 0.442
Post-Split Price
142.6175
Before
After
Feb 1, 2021
Feb 1, 2021
Split 1-for-6
/0.16666666666667
Pre-Split Price
1 864.125 0.8285
Post-Split Price
1 762.5004
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.13 0.13 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.41 8.41 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Dec 30, 2025
Adicet Bio Inc
NASDAQ:ACET
1-for-16
/16
0.4921 0.4921 USD 7.93 7.93 USD
Load More

Moleculin Biotech Inc
Glance View

Market Cap
7.2m USD
Industry
Biotechnology

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2016-06-02. The firm has a pipeline of clinical programs for the treatment of highly resistant cancers and viruses. The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066 Portfolio (including lead drug candidates WP1066 and WP1220) represents a class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. WP1066 is its flagship Immune/Transcription Modulator. An analog of WP1066, referred to as WP1220, is related to the use of the molecule in the topical treatment of psoriasis. The firm's WP1122 Portfolio and similar molecules focused on inhibitors of glycolysis and glycosylation.

MBRX Intrinsic Value
3.25 USD
Overvaluation 10%
Intrinsic Value
Price
Back to Top